References

Addonizio VP Jr, Fisher CA, Kappa JR, Ellison N. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374). Surgery 102: 796-807,1987.

Antoniou T, Kapetanakis EI, Theodoraki K, Rellia P, Thanapoulos A, Kotiou M, Zarkalis D, Alivizatos P. Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost. Heart Surg Forum 5:354-357, 2002.

Aouifi A, Blanc P, Piriou V, Bastien OH, French P, Hanss M, Lehot JJ. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocy-topenia. Ann Thorac Surg 71:678-683, 2001.

Bauer TL, Arepally G, Konkle BA, Mestichelli B, Shapiro SS, Cines DB, Poncz M, McNulty S, Amiral J, Hauck WW, Edie RN, Mannion JD. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 95:1242-1246,1997.

Cannon MA, Butterworth J, Riley RD, Hyland JM. Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery. Ann Thorac Surg 77:711-713, 2004.

Carrier M, Robitaille D, Perrault LP, Pellerin M, Page P, Cartier R, Bouchard D. Heparin versus danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial. J Thorac Cardiovasc Surg 125:325-329, 2003.

Chong BH, Berndt MC. Heparin-induced thrombocytopenia. Blut 58:53-57, 1989.

Dyke CM, Smedira N, Koster A, Aronson S, McCarthy HL 2nd, Kirshner R, Lincoff AM, Spiess BD. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 131:533-539, 2006.

Dyke CM, Aldea G, Koster A, Smedira N, Avery E, Aronson S, Spiess BD, Lincoff AM. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or anti-platelet factor 4/heparin antibodies. Ann Thorac Surg 2007; in press.

Edmunds LH Jr. Blood-surface interactions during cardiopulmonary bypass. J Cardio-vasc Surg 8:404-410, 1993.

Edwards JT, Hamby JK, Worrall NK. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 75:1622-1624, 2003.

Furukawa K, Ohteki H, Hirahara K, Narita Y, Koga S. The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations. J Thorac Cardio-vasc Surg 122:1255-1257, 2001.

Gasparovic H, Nathan NS, Fitzgerald D, Aranki SF. Severe argatroban-induced coagu-lopathy in a patient with a history of heparin-induced thrombocytopenia. Ann Thorac Surg 78:e89-e91, 2004.

Grocott HP, Root J, Berkowitz SD, deBruijn N, Landolfo K. Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium. J Cardiothorac Vasc Anesth 11: 875-877,1997.

Iqbal O, Tobu M, Aziz S, Gerdisch M, DaValle M, Demir M, Hoppensteadt DA, Ahmad S, Walenga JM, Fareed J. Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization. J Card Surg 20:42-51, 2005.

Kappa JR, Horn D, Mclntosh CL, Fisher CA, Ellison N, Addonizio VP. Iloprost (ZK36374), a new prostacyclin analogue, permits open cardiac surgery in patients with heparin-induced thrombocytopenia. Surg Forum 36:285-286, 1985.

Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin North Am 14:445-457, 2000.

Kieta DR, McCammon AT, Holman WL, Nielsen VG. Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation. Anesth Analg 96:956-958, 2003.

Koster A, Hansen R, Grauhan O, Hausmann H, Bauer M, Hetzer R, Kuppe H, Mertzlufft F. Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II. J Cardiothorac Vasc Anesth 14:249-252, 2000a.

Koster A, Pasic M, Bauer M, Kuppe H, Hetzer R. Hirudin as anticoagulant for cardiopulmonary bypass: importance of reoperative renal function. Ann Thorac Surg 69:37-41, 2000b.

Koster A, Merkle F, Hansen R, Loebe M, Kuppe H, Hetzer R, Crystal GJ, Mertzlufft F. Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems. Aneth Analg 91:265-269, 2000c.

Koster A, Kuppe H, Crystal G, Mertzlufft F. Cardiovascular surgery without cardio-pulmonary bypass in patients with heparin-induced thrombocytopenia type II using anticoagulation with recombinant hirudin. Anesth Analg 90:292-298, 2000d.

Koster A, Loebe M, Merztlufft F, Kuppe H, Hetzer R. Cardiopulmonary bypass in a patient with heparin induced thrombocytopenia II and impaired renal function using heparin and platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant. Ann Thorac Surg 70:2160-2161, 2000e.

Koster A, Kukucka M, Bach F, Meyer O, Fischer T, Mertzlufft F, Loebe M, Hetzer R, Kuppe H. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiol 94:245-251, 2001a.

Koster A, Meyer O, Fischer T, Kuschka M, Krabatsch T, Bauer M, Kuppe H, Hetzer R. One-year experience with the platelet glycoprotein Ilb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombo-cytopenia type II. J Thorac Cardiovasc Surg 122:1254-1255, 2001b.

Koster A, Chew D, Grundel M, Bauer M, Kuppe H, Spiess BD. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary-bypass. Anesth Analg 96:383-386, 2003a.

Koster A, Chew D, Gruendel M, Hausmann H, Grauhan O, Kuppe H, Spiess BD. An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study. Anesth Analg 96:1316-1319, 2003b.

Koster A, Spiess BD, Chew DP, Krabatsch T, Tambeur L, DeAnda A, Hetzer R, Kuppe H, Smedira NG, Lincoff AM. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol 93:356-359, 2004a.

Koster A, Chew D, Merkle F, Gruendel M, Jurmann M, Kuppe H, Oertel R. Extra-corporeal elimination of large concentrations of tirofiban by zero-balanced ultrafiltration during cardiopulmonary bypass: an in vitro investigation. Anesth Analg 99:989-92, 2004b.

Koster A, Yeter R, Buz S, Kuppe H, Hetzer R, Lincoff AM, Dyke CM, Smedira NG, Spiess BD. Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin: results of a pilot study. J Thorac Cardiovasc Surg 129:1391-1394, 2005.

Koster A, Buz S, Hetzer R, Kuppe H, Breddin K, Harder S. Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiac surgery with cardiopulmonary bypass: first results from the ARG-E03 trial. J Thorac Cardiovasc Surg 132:699-700, 2006.

Koster A, Dyke CM, Aldea G, Smedira NG, McCarthy HL 2nd, Aronson S, Hetzer R, Avery E, Spiess BD, Lincoff M. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 83:572-577, 2007.

Koza MJ, Walenga JM, Fareed J, Pifarre R. A new approach in monitoring recombinant hirudin during cardiopulmonary bypass. Semin Thromb Hemost 19:90-96,1993.

Kraenzler EJ, Starr NJ. Heparin-associated thrombocytopenia: management of patients for open heart surgery. Case reports describing the use of iloprost. Anesthesiology 69:964-967,1988.

Lewis BE, Johnson SA, Grassman ED, Wrona LL. Argatroban as an anticoagulant for coronary procedures in patients with HIT antibody. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, 301-308, 1997a.

Lewis BE, Walenga JM, Pifarre R, Fareed J. Argatroban in the management of patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, 223-229, 1997b.

Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang I-K,Rifkin SD, Moran J, Hursting MJ, Kelton JG for the ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103:1838-1843, 2001.

Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG, Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 163:1849-1856, 2003.

Long RW. Management of patients with heparin-induced thrombocytopenia requiring cardiopulmonary bypass. J Thorac Cardiovasc Surg 89:950-951, 1985.

Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 70:554-561,1993.

Magnani HN, Beijering RJR, ten Cate JW, Chong BH. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, 487-500,1997.

Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 95:967-981, 2006.

Makhoul RG, McCann RL, Austin EH, Greenberg CS, Lowe JE. Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery. Ann Thorac Surg 43:617-621, 1987.

Merry AF, Raudkivi PJ, Middleton NG, McDougall JM, Nand P, Mills BP, Webber BJ, Frampton CM, White HD. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 77:925-931, 2004.

Mertzlufft F, Kuppe H, Koster A. Management of urgent high-risk cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and coexisting disorders of renal function: use of heparin and epoprostenol combined with online monitoring of platelet function. J Cardiothorac Vasc Anesth 14:304-308, 2000.

Nishida S, Fujita T, Kohno N, Atoda H, Morita T, Takeya H, Kido I, Paine MJI, Kawabata S, Iwanaga S. cDNA cloning and deduced amino acid sequence of prothrombin activator (ecarin) from Kenyan Echis carinatus venom. Biochemistry 34:1771-1778,1995.

Ohno H, Higashidate M, Yokosuka T. Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary bypass surgery. Heart Vessels 18: 40-42, 2003.

Olinger GN, Hussey CV, Olive JA, Malik MI. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation. J Thorac Cardio-vasc Surg 87:673-677, 1984.

Palmer Smith J, Walls JT, Muscato MS, Scott McCord E, Worth ER, Curtis JJ, Silver D. Extracorporeal circulation in a patient with heparin-induced thrombocytopenia. Anesthesiology 62:363-365, 1985.

Pötzsch B, Iversen S, Riess FC, Tzanova N, Seelig C, Nowak G, Müller-Berghaus G. Recombinant hirudin as an anticoagulant in open-heart surgery: a case report [abstr]. Ann Hematol 68(Suppl 2):A46,1993.

Pötzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Müller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass—assessment of the whole blood ecarin clotting time. Thromb Haemost 77:920-925,1997.

Pötzsch B, Klövekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia [letter]. N Engl J Med 343:515, 2000.

Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, Gruel Y. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low molecular weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 99: 2530-2536, 1999.

Riess FC, Löwer C, Seelig C, Bleese N, Kormann J, Müller-Berghaus G, Pötzsch B. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. Thorac Cardiovasc Surg 110:265-267, 1995.

Riess FC, Pötzsch B, Bader K, Bleese N, Greinacher A, LVwer C, Madlener K, Müller-Berghaus G. A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery. Eur J Cardiothorac Surg 10:386-388, 1996.

Riess FC, Pötzsch B, Mueller-Berghaus G. Recombinant hirudin as an anticoagulant during cardiac surgery. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, 197-222, 1997.

Selleng S, Lubenow N, Wollert HG, Mullejans B, Greinacher A. Emergency cardiopul-monary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin. Ann Thorac Surg 71:1041-1042, 2001.

Slaughter TF, LeBleu TH, Douglas JM Jr, Leslie JB, Parker JK, Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 80:520-526,1994.

Smedira NG, Dyke CM, Koster A, Jurmann M, Bhatia DS, McCarthy HL 2nd, Lincoff AM, Spiess BD, Araonson S. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: results of the EVOLUTION-OFF study. J Thorac Cardio-vas Surg 131:686-692, 2006.

Trossaert M, Gaillard A, Commin PL, Amiral J, Vissac AM, Fressinaud E. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 101:653-655, 1998.

Van Dyck MJ,Lavenne-Pardonge E, Azerad M-A, Matta AG, Moriau M, Comunale ME. Thrombosis after the use of heparin-coated cardiopulmonary bypass circuit in a patient with heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth 10:809-815,1996.

Veale JJ, McCarthy HM, palmer G, Dyke CM. Use of bivalirudin as an anticoagulant during cardiopulmonary bypass. J Extracorp Technol 37:296-302, 2005.

Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: platelet factor 4 complexes. J Lab Clin Med 128:376-383, 1996.

Walenga JM, Bakhos M, Messmore HL, Koza M, Wallock M, Orfei E, Fareed J, Pifarre R. Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model. Blood Coagul Fibrinolysis 2:105-111,1991.

Walls JT, Curtis JJ, Silver D, Boley TM. Heparin-induced thrombocytopenia in patients who undergo open heart surgery. Surgery 108:686-693, 1990.

Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 76:2121-2131, 2003.

Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344:1286-1292, 2001.

Warkentin TE, Koster A. Bivalirudin: a review. Expert Opin Pharmacother 6:1349-1371, 2005.

Warkentin TE, Sheppard JI. No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost 4:281-282, 2006.

Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk of heparin-induced thrombocytopenia. Blood 96: 1703-1708, 2000.

Warkentin TE, Dunn GL, Cybulsky IJ. Off-pump coronary artery bypass grafting for acute heparin-induced thrombocytopenia. Ann Thorac Surg 72:1730-1732, 2001.

Zucker ML, Koster A, Prats J, Laduca FM. Sensitivity of a modified ACT test to levels of bivalirudin used during cardiac surgery. J Extra Corp Technol 37:364-368, 2005.

0 0

Post a comment